Section Arrow
Quote
KOD.NASDAQ
- Kodiak Sciences
Quotes are at least 15-min delayed:2026/08/02 06:38 EDT
Regular Hours
Last
 41.58
-0.92 (-2.16%)
Day High 
42.925 
Prev. Close
42.5 
1-M High
44.85 
Volume 
426.73K 
Bid
40.8
Ask
41.65
Day Low
40.35 
Open
42.45 
1-M Low
35.77 
Market Cap 
2.66B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 41.5 
20-SMA 40.95 
50-SMA 37.38 
52-W High 47.8417 
52-W Low 6.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.17/-2.92
Enterprise Value
2.71B
Balance Sheet
Book Value Per Share
1.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.